Afamelanotide for Erythropoietic Protoporphyria | Zendy

Janneke G. Langendonk | Zendy; Manisha Balwani | Zendy; Karl E. Anderson | Zendy; Herbert L. Bonkovsky | Zendy; A. Anstey | Zendy; D. Montgomery Bissell | Zendy; Joseph R. Bloomer | Zendy; Chris Edwards | Zendy; Norbert Neumann | Zendy; Charles Parker | Zendy; John D. Phillips | Zendy; Henry W. Lim | Zendy; Iltefat Hamzavi | Zendy; JeanCharles Deybach | Zendy; Raili Kauppinen | Zendy; Lesley E. Rhodes | Zendy; Jorge Frank | Zendy; Gillian Murphy | Zendy; Francois Karstens | Zendy; Eric J.G. Sijbrands | Zendy; Felix W.M. de Rooij | Zendy; Mark Lebwohl | Zendy; Hetanshi Naik | Zendy; Colin R. Goding | Zendy; J.H.P. Wilson | Zendy; Robert J. Desnick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Afamelanotide for Erythropoietic Protoporphyria

Author(s) -

Janneke G. Langendonk,

Manisha Balwani,

Karl E. Anderson,

Herbert L. Bonkovsky,

A. Anstey,

D. Montgomery Bissell,

Joseph R. Bloomer,

Chris Edwards,

Norbert Neumann,

Charles Parker,

John D. Phillips,

Henry W. Lim,

Iltefat Hamzavi,

JeanCharles Deybach,

Raili Kauppinen,

Lesley E. Rhodes,

Jorge Frank,

Gillian Murphy,

Francois Karstens,

Eric J.G. Sijbrands,

Felix W.M. de Rooij,

Mark Lebwohl,

Hetanshi Naik,

Colin R. Goding,

J.H.P. Wilson,

Robert J. Desnick

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1411481

Subject(s) - medicine , erythropoietic protoporphyria , placebo , european union , randomization , adverse effect , phototoxicity , quality of life (healthcare) , randomized controlled trial , photodermatosis , surgery , anesthesia , photochemistry , in vitro , dna damage , chemistry , genetics , biology , dna , biochemistry , porphyrin , nursing , xeroderma pigmentosum , protoporphyrin , alternative medicine , business , pathology , economic policy

Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research